Genomic alterations of the underlying lymphoma (e.g., TP53 mutations, copy number changes, chromosomal instability) and the tumor immune environment are additional response determinants, which can be associated with the metabolic tumor volume (MTV) as determined by 18FDG-PET/CT imaging [21–29]. The gene discussed is TP53; the disease is neoplasm.